X
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
SNB-101 (SN-38) is an anticancer agent that is the world's first nanoparticle formulation of the anticancer drug SN-38. SN-38 is an active metabolite of Irinotecan, being evaluated for the treatment of small cell lung cancer.
Lead Product(s): Irinotecan Hydrochloride
Therapeutic Area: Oncology Product Name: SNB-101
Highest Development Status: Phase IProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable May 09, 2024
Details:
SNB-101 (SN-38) is an anticancer agent that is the world's first nanoparticle formulation of the anticancer drug SN-38. It uses a delivery system sophisticatedly designed via dual nano-micelle technology. It is being evaluated for the treatment of pancreatic cancer.
Lead Product(s): Irinotecan Hydrochloride
Therapeutic Area: Oncology Product Name: SNB-101
Highest Development Status: Phase IProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable February 29, 2024
Details:
SNB-101 is the world's first product to use the active metabolite (SN-38) of Irinotecan as an API, and dual nano-micelle technology which is a core platform technology of SN Bioscience is applied.
Lead Product(s): Irinotecan Hydrochloride
Therapeutic Area: Oncology Product Name: SNB-101
Highest Development Status: Phase IProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable July 20, 2023
Details:
Through this contract, Boryeong will have exclusive manufacturing and distribution rights in Korea for SNA-001. SNA-001 is a product that electrostatically binds cytotoxic anticancer drugs to albumin using albumin present in human blood as a drug carrier.
Lead Product(s): Paclitaxel
Therapeutic Area: Oncology Product Name: SNA-001
Highest Development Status: Phase IProduct Type: Small molecule
Partner/Sponsor/Collaborator: Boryeong
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Licensing Agreement January 26, 2023
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
